目的： 研究重组人MUC1-MBP的抗肿瘤作用。方法：用重组人MUC1-MBP皮下注射途径免疫健康鼠，采用MTT法测定小鼠抗MUC1特异的CTL活性；通过免疫鼠成瘤及荷瘤鼠治疗实验检测其对肿瘤的预防和治疗作用。结果：MUC1-MBP免疫鼠CTL对MCF-7及Lewis肺癌细胞的杀伤率分别为(47.7±4.3) %和(67.5±6.5) %；免疫鼠成瘤结果免疫组小鼠共长5个肿瘤，存活时间明显延长，对照组共长51个，平均生存时间23 d；荷瘤鼠治疗结果显示治疗组小鼠肿瘤平均体积386 mm3，对照组小鼠肿瘤平均体积4 000 mm3。结论：重组人MUC1-MBP具有明显的治疗、预防肿瘤和抑制肿瘤转移的作用,有希望发展成人类抗肿瘤疫苗。

Objective:To study the anti-tumor effect of recombinant human MUC1-MBP. Methods: The C57BL/6 mice were in oculated with MUC1-MBP by subcutaneous. MUC1 specific CTL activity of spleen were determined by MTT; The effects on prevention and treatment of tumor were observed by establishing lewis lung cancer-carrying mice. Results:The cytotoxicity of CTL from immunized mice to the MCF7 and Lewis lung cancer cells respectively was (47.7±4.3) % and (67.5 ±6.5) %; 5×105 lewis lung cancer cells following immunization were injected iv into C57BL/6 mice, after three weeks, the number of lung and tail tumor colonies was 51 and 5 for PBS and MUC1-MBP groups respectively and the suvival time was significantly delayed in immunized mice. The average volume of tumors in mice with MUC1-MBP was 386 mm3 wherea control group was 4 000 mm3 at tumor treating experiment. Conclusions:Recombinant human MUC1-MBP have significantly effects on prevention, treatment and inhibiting metastases of tumor. Our results suggested that the recombinant MUC1-MBP might be used to develop protein vaccine against human carcinoma.

国家自然科学基金项目（NO39670686）及教育部跨世纪优秀人才培养计划资助